Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT, Chini EN.

Clin Cancer Res. 2014 Jan 1;20(1):120-30. doi: 10.1158/1078-0432.CCR-13-0150. Epub 2013 Sep 11.

2.

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.

Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.

Cancer Lett. 2016 Aug 28;379(1):1-11. doi: 10.1016/j.canlet.2016.05.024. Epub 2016 May 24.

PMID:
27233476
3.

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5.

4.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

5.

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ, Ashworth A.

EMBO Mol Med. 2012 Oct;4(10):1087-96. doi: 10.1002/emmm.201201250. Epub 2012 Aug 30.

6.

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC.

Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3.

7.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

8.

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A.

PLoS One. 2009 Nov 19;4(11):e7897. doi: 10.1371/journal.pone.0007897.

9.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.

Exp Hematol. 2013 Jun;41(6):547-557.e2. doi: 10.1016/j.exphem.2013.02.008. Epub 2013 Feb 19.

10.

NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression.

Thakur BK, Lippka Y, Dittrich T, Chandra P, Skokowa J, Welte K.

Biochem Biophys Res Commun. 2012 Apr 20;420(4):714-20. doi: 10.1016/j.bbrc.2012.03.017. Epub 2012 Mar 10.

PMID:
22430142
11.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo MS, Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G.

J Biol Chem. 2013 Feb 1;288(5):3500-11. doi: 10.1074/jbc.M112.394510. Epub 2012 Dec 13.

12.

FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.

Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W, Garten A.

Biochem Biophys Res Commun. 2015 Mar 6;458(2):334-40. doi: 10.1016/j.bbrc.2015.01.111. Epub 2015 Feb 3.

PMID:
25656579
13.

Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.

Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, Bianchi G, Vigliarolo T, Nahimana A, Nencioni A, Raffaelli N, Bruzzone S.

Oncotarget. 2016 Jan 19;7(3):2968-84. doi: 10.18632/oncotarget.6502.

14.

NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.

Hong SM, Park CW, Kim SW, Nam YJ, Yu JH, Shin JH, Yun CH, Im SH, Kim KT, Sung YC, Choi KY.

Oncogene. 2016 Jul 7;35(27):3544-54. doi: 10.1038/onc.2015.415. Epub 2015 Nov 16.

PMID:
26568303
15.

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Tan B, Dong S, Shepard RL, Kays L, Roth KD, Geeganage S, Kuo MS, Zhao G.

J Biol Chem. 2015 Jun 19;290(25):15812-24. doi: 10.1074/jbc.M114.632141. Epub 2015 May 5.

16.

Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.

Pittelli M, Cavone L, Lapucci A, Oteri C, Felici R, Niccolai E, Amedei A, Chiarugi A.

Immunol Cell Biol. 2014 Feb;92(2):191-9. doi: 10.1038/icb.2013.85. Epub 2013 Nov 26.

PMID:
24275857
17.

Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.

Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, Fang SH, Lu YB, Hu H, Wei EQ, Zhang WP.

Eur J Pharmacol. 2012 Jan 15;674(2-3):163-70. doi: 10.1016/j.ejphar.2011.11.017. Epub 2011 Nov 19.

PMID:
22119381
18.

Up-regulation of nicotinamide phosphoribosyltransferase and increase of NAD+ levels by glucose restriction extend replicative lifespan of human fibroblast Hs68 cells.

Yang NC, Song TY, Chang YZ, Chen MY, Hu ML.

Biogerontology. 2015 Feb;16(1):31-42. doi: 10.1007/s10522-014-9528-x. Epub 2014 Aug 22.

PMID:
25146190
19.

EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.

Zucal C, D'Agostino VG, Casini A, Mantelli B, Thongon N, Soncini D, Caffa I, Cea M, Ballestrero A, Quattrone A, Indraccolo S, Nencioni A, Provenzani A.

BMC Cancer. 2015 Nov 5;15:855. doi: 10.1186/s12885-015-1845-1.

20.

NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages.

Venter G, Oerlemans FT, Willemse M, Wijers M, Fransen JA, Wieringa B.

PLoS One. 2014 May 13;9(5):e97378. doi: 10.1371/journal.pone.0097378. eCollection 2014.

Supplemental Content

Support Center